 36 PM / Updated 9 minutes ago BRIEF-Avadel Pharma Receives Orphan Drug Designation From FDA For FT 218 Reuters Staff 1 Min Read 
Jan 10 (Reuters) - Avadel Pharmaceuticals Plc: 
* AVADEL PHARMACEUTICALS RECEIVES ORPHAN DRUG DESIGNATION FROM FDA FOR FT 218 FOR THE TREATMENT OF NARCOLEPSY Source text for Eikon: Further company coverage: